GlaxoSmithKline Pharma Net Up 6 Percent (India)
This article was originally published in PharmAsia News
GlaxoSmithKline's India division increased its net profit by 6 percent during second quarter 2007 compared to last year. The Indian division is developing four new anti-diabetic products, and this year has successfully launched two such products, Windia and Windamet. GSK's total sales fell by 2.1 percent, mostly due to the sale of Virbac Animal Health in 2006, one reason its operations efficacy and net profit increased in second quarter 2007. The company also is selling Qualigens Fine Chemicals to India-based Thermo Electron LLS India for Rs 240 crore. (Click here for more
You may also be interested in...
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.